Table 1.
Characteristics of the Global Population
| Characteristic | TBF (n = 968) | Treo (n = 155) | P-value |
|---|---|---|---|
| Median age at transplant, y (range) | 53 (18–74) | 59 (18–76) | <0.001 |
| Patient gender | |||
| Male | 526 (54) | 92 (59) | 0.24 |
| Female | 442 (46) | 63 (41) | |
| Secondary AML | 112 (12) | 24 (16) | 0.17 |
| Cytogenetic risk (MRC) | 0.16 | ||
| Good | 54 (6) | 10 (7) | |
| Intermediate | 529 (54) | 98 (63) | |
| Adverse | 190 (20) | 25 (16) | |
| Missing | 195 (20) | 22 (14) | |
| FLT3-ITD mutation | 0.9 | ||
| FLT3-ITD | 178 (35) | 30 (34) | |
| FLT3 wt | 335 (65) | 58 (66) | |
| Missing | 455 | 67 | |
| NPM1 mutation | 0.7 | ||
| NPM1 mutated | 183 (38) | 29 (36) | |
| NPM1 wt | 293 (62) | 51 (64) | |
| Missing | 492 | 75 | |
| Disease status at HSCT | |||
| CR1 | 732 (76) | 128 (83) | 0.06 |
| CR2 | 236 (24) | 27 (17) | |
| Disease risk index | 0.34 | ||
| Low | 54 (6%) | 10 (7%) | |
| Intermediate | 716 (74%) | 121 (78%) | |
| High | 198 (20%) | 24 (15%) | |
| Karnofsky performance score | 0.95 | ||
| ≥90 | 795 (82) | 127 (82) | |
| <90 | 173 (18) | 28 (18) | |
| Median year of HSCT (range) | 2018 (2011–2020) | 2019 (2012–2020) | 0.001 |
| Conditioning intensity | 0.12 | ||
| MAC | 582 (60) | 83 (54) | |
| RIC | 386 (40) | 72 (46) | |
| GVHD prophylaxis (other than PTCy) | |||
| MMF + cyclosporine | 744 (77) | 28 (18) | |
| MMF + tacrolimus | 117 (12) | 55 (36) | |
| MMF + sirolimus | 13 (1) | 64 (41) | |
| Other | 94 (10) | 8 (5) | |
| ATG | 0.48 | ||
| Yes | 119 (12) | 16 (10) | |
| No | 849 (88) | 139 (90) | |
| Stem cell source | < 0.001 | ||
| PBSC | 500 (52) | 136 (88) | |
| BM | 468 (48) | 19 (12) | |
| Female donor/male recipient | 184 (19) | 34 (22) | 0.4 |
| Median follow-up, mo (95% CI) | 27 (25-30) | 18 (15-23) | < 0.001 |
AML = acute myeloid leukemia; ATG = antithymocyte globulin; BM = bone marrow; CI = confidence interval; CR = complete remission; HSCT = hematopoietic stem cell transplant; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; MRC = Medical Research Council Cytogenetic Classification; PBSC = peripheral blood stem cells; RIC = reduced intensity conditioning; TBF = thiotepa, busulfan, fludarabine; Treo = treosulfan-based regimen; wt = wild type.
Unless otherwise noted, data are expressed as n (%).